Clinical Trial Update: Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial in heart transplant recipients evaluating CellCept (mycophenolate mofetil) with Rapamune (sirolimus) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Rapamune (sirolimus)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Heart Transplantation | Phase 4 | Status: TERMINATED